Skip to main content

Advertisement

SpringerLink
Log in

Hormonal prostate cancer therapies and cardiovascular disease: a systematic review

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Therapeutic intervention for prostate cancer mostly relies on eliminating circulating androgen or antagonizing its effect at the cellular level. As the use of endocrine therapies grows, an under-reported incidence of cardiovascular toxicities occurs in prostate cancer patients. In this review, we summarize data of clinical studies, investigating the cardiovascular and metabolic alterations associated with the use of old and new endocrine drugs (gonadotropin-releasing hormone [GnRH] agonists and antagonists, androgen receptor inhibitors, 17α-hydroxylase/c-17,20-lyase [CYP17] inhibitor) in prostate cancer. To date, studies looking for links between cardiovascular complications and hormone-mediated therapies in prostate cancer have reached conflicting results. Several confounding factors, such as age of patients and related cardiovascular liability, other comorbidities, and use of concomitant drugs, have to be carefully evaluated in future clinical trials. Further research is needed given the continuous advancements being made in prostate cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

    Article  Google Scholar 

  2. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL 3rd, Bennett CL, Scher HI, American Society of Clinical Oncology (2007) Initial hormonal management of androgen sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25:1596–1605

    PubMed  CAS  Google Scholar 

  3. Sargos P, Mottet N, Bellera C, Richaud P (2019) Long-term androgen deprivation, with or without radiotherapy, un locally-advanced prostate cancer: updated results from a phase III randomized trial. BJU Int. https://doi.org/10.1111/bju.i4768

  4. Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE (2011) A phase III extension trial with 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 186(3):889–897

    PubMed  CAS  Google Scholar 

  5. Tosco L, Briganti A, D’amico AV et al (2019) Systematic review of systemic therapies and therapeutic combinations with local treatments for high-risk localized prostate cancer. Eur Urol 75(1):44–60

    PubMed  Google Scholar 

  6. Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PMP, Sundar S, van der Steen-Banasik EM, Armstrong J, Bosset JF, Herrera FG, Pieters B, Slot A, Bahl A, Ben-Yosef R, Boehmer D, Scrase C, Renard L, Shash E, Coens C, van den Bergh ACM, Collette L (2016) Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol 34:1748–1756

    PubMed  CAS  Google Scholar 

  7. Iversen P, Tyrrel CJ, Kaisary AV et al (2000) Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow up. J Urol 164(5):1579–1582

    PubMed  CAS  Google Scholar 

  8. Azaka H, Hinotsu S, Usami M et al (2009) Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up for a phase 3, double-blind, randomized study for survival. Cancer 115(15):3437–3445

    Google Scholar 

  9. Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N (2002) Systematic review and meta-analyses of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95(2):361–376

    PubMed  CAS  Google Scholar 

  10. Omlin A, Pezaro C, Mukherji D, Mulick Cassidy A, Sandhu S, Bianchini D, Olmos D, Ferraldeschi R, Maier G, Thompson E, Parker C, Attard G, de Bono J (2013) Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol 64:300–306

    PubMed  Google Scholar 

  11. Moreira DM, Howard LE, Sourbeer KN et al (2017) Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH. Clin Genitourin Cancer 15(1):60–66.e2

    PubMed  Google Scholar 

  12. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, COU-AA-302 Investigators (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138–148

    PubMed  CAS  Google Scholar 

  13. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, de Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, COU-AA-302 Investigators (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152–160

    PubMed  CAS  Google Scholar 

  14. De Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005

    PubMed  PubMed Central  Google Scholar 

  15. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS, COU-AA-301 Investigators (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992

    PubMed  CAS  Google Scholar 

  16. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, de Porre P, Kheoh T, Park YC, Todd MB, Chi KN (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352–360

    PubMed  CAS  Google Scholar 

  17. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR, STAMPEDE Investigators (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377(4):338–351

    PubMed  PubMed Central  CAS  Google Scholar 

  18. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187–1197

    PubMed  CAS  Google Scholar 

  19. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B, PREVAIL Investigators (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424–433

    PubMed  PubMed Central  Google Scholar 

  20. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B (2017) Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol 71(2):151–154

    PubMed  CAS  Google Scholar 

  21. Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung D, Krivoshik A, Sternberg CN (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378(26):2465–2474

    PubMed  PubMed Central  CAS  Google Scholar 

  22. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381:121–131. https://doi.org/10.1056/NEJMoa1903835

    Article  PubMed  CAS  Google Scholar 

  23. Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J (2016) Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation 133:537–541

    PubMed  PubMed Central  Google Scholar 

  24. Gupta D, Lee Chuy K, Yang JC, Bates M, Lombardo M, Steingart RM (2018) Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. J Oncol Pract 14(10):580–587

    PubMed  Google Scholar 

  25. O’Farrell S, Garmo H, Holmberg L et al (2015) Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33:1243–1251

    PubMed  Google Scholar 

  26. Barber M, Nguyen LS, Wassermann J, Spano JP, Funck-Brentano C, Salem JE (2019) Cardiac arrhythmia considerations of hormone cancer therapies. Cardiovasc Res 115:878–894

    PubMed  CAS  Google Scholar 

  27. Veccia A, Maines F, Kinspergher S, Galligioni E, Caffo O (2017) Cardiovascular toxicities of systemic treatments of prostate cancer. Nat Rev Urol 14(4):230–243

    PubMed  CAS  Google Scholar 

  28. Levine GN, D’Amico AV, Berger P et al (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121(6):833–840

    PubMed  PubMed Central  Google Scholar 

  29. Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TLJ, Ke C, Leder BZ, Goessl C (2012) Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol 30(26):3271–3276

    PubMed  PubMed Central  Google Scholar 

  30. Keating NL, O’Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24(27):4448–4456

    PubMed  CAS  Google Scholar 

  31. Rezaei MM, Rezaei MM, Ghoreifi A, Kerigh BF (2016) Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy. Can Urol Assoc J 10(9–10):E300–E305

    PubMed  PubMed Central  Google Scholar 

  32. Gagliano-Jucà T, Travison TG, Kantoff PW et al (2018) Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer. J Endocr Soc 2(5):485–496

    PubMed  PubMed Central  Google Scholar 

  33. Smith MR, Klotz L, Persson BE, Olesen TK, Wilde AAM (2010) Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol 184(6):2313–2319

    PubMed  PubMed Central  CAS  Google Scholar 

  34. Salem JE, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E, Maupain C, Moslehi JJ, Badilini F, Haroche J, Gougis P, Fressart V, Glazer AM, Hidden-Lucet F, Touraine P, Lebrun-Vignes B, Roden DM, Bachelot A, Funck-Brentano C (2018) Hypogonadism as a reversible cause of torsades de pointes in men. Circulation 138:110–113

    PubMed  PubMed Central  Google Scholar 

  35. Lubart E, Yarovoy A, Gal G, Krakover R, Leibovitz A (2015) QT interval lenght in elderly prostatic cancer patients on anti-testosterone treatment. Isr Med Assoc J 17:356–359

    PubMed  Google Scholar 

  36. Zareba P, Duivenvoorden W, Leong DP, Pinthus JH (2016) Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol 8:118–129

    PubMed  CAS  Google Scholar 

  37. Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y (2014) Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One 9:e107516

    PubMed  PubMed Central  Google Scholar 

  38. Meng F, Zhu S, Zhao J, Vados L, Wang L, Zhao Y, Zhao D, Niu Y (2016) Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. BMC Cancer 16:180

    PubMed  PubMed Central  Google Scholar 

  39. Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, van Hemelrijck M (2015) Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 68(3):386–396

    PubMed  Google Scholar 

  40. Gandaglia G, Sun M, Popa I, Schiffmann J, Trudeau V, Shariat SF, Trinh QD, Graefen M, Widmer H, Saad F, Briganti A, Montorsi F, Karakiewicz PI (2015) Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study. Clin Genitourin Cancer 13(3):e123–e130

    PubMed  Google Scholar 

  41. Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, Choueiri TK, D’Amico AV, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL (2015) Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int 116(3):358–365

    PubMed  CAS  Google Scholar 

  42. Monzò-Gardiner JI, Herranz-Amo F (2015) Cardiovascular mortality in patients with prostate cancer exposed to androgen deprivation therapy. Actas Urol Esp 39(8):518–522

    PubMed  Google Scholar 

  43. Lester-Coll NH, Johnson S, Magnuson WJ et al (2016) Weighing risk of cardiovascular mortality against potential benefit of hormonal therapy in intermediate-risk prostate cancer. J Natl Cancer Inst 109(6). https://doi.org/10.1093/jnci/djw281

  44. Haque R, Ulcickas Yood M, Xu X et al (2017) Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. Br J Cancer 117(8):1233–1240

    PubMed  PubMed Central  CAS  Google Scholar 

  45. Zapatero A, Guerrero A, Maldonado X, Álvarez A, González-San Segundo C, Cabeza Rodriguez MA, Macías V, Pedro Olive A, Casas F, Boladeras A, Martín de Vidales C, Vázquez de la Torre ML, Calvo FA (2016) Late radiation and cardiovascular adverse effects after androgen deprivation and high-dose radiation therapy in prostate cancer: results from the DART 01/05 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 96(2):341–348

    PubMed  Google Scholar 

  46. Nguyen PL, Je Y, Schutz FAB, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK (2011) Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306(21):2359–2366

    PubMed  CAS  Google Scholar 

  47. Wilcox C, Kautto A, Steigler et al (2012) Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term. Oncology 82(1):56–58

    PubMed  CAS  Google Scholar 

  48. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368(14):1314–1325

    PubMed  PubMed Central  CAS  Google Scholar 

  49. Sciarra A, Fasulo A, Ciardi A, Petrangeli E, Gentilucci A, Maggi M, Innocenzi M, Pierella F, Gentile V, Salciccia S, Cattarino S (2016) A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine (Baltimore) 95(27):e3845

    CAS  Google Scholar 

  50. Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J (2014) Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65(3):565–573

    PubMed  CAS  Google Scholar 

  51. Scailteux LM, Vincendeau S, Balusson F, Leclercq C, Happe A, le Nautout B, Polard E, Nowak E, Oger E (2017) Androgen deprivation therapy and cardiovascular risk: no meaningful difference between GnRH antagonist and agonists - a nationwide population-based cohort study based on 2010-2013 French health insurance data. Eur J Cancer 77:99–108

    PubMed  CAS  Google Scholar 

  52. Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, Eckel RH, Keane TE, Shore ND, Dahdal DN, Beveridge TJR, Marshall DC (2017) The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal and cognitive effects associated with androgen deprivation therapy. Urol Oncol 35(5):183–191

    PubMed  CAS  Google Scholar 

  53. Slovin SF, Melloni C, Mansor-Lefebvre S et al (2018) A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist). J Clin Oncol 36(suppl):TPS395

    Google Scholar 

  54. Melong N, Steele S, MacDonald M, Holly A, Collins CC, Zoubeidi A, Berman JN, Dellaire G (2017) Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia. Sci Rep 7:14698

    PubMed  PubMed Central  Google Scholar 

  55. Pozniak A (2008) New drugs: enzalutamide. J HIV Ther 13:27–33

    PubMed  Google Scholar 

  56. Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, van Os S, Hasabou N, Wang F, Bhattacharya S, Heidenreich A (2016) Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol 17(2):153–163

    PubMed  CAS  Google Scholar 

  57. Joshua AM, Shore ND, Saad F, Chi KN, Olsson CA, Emmenegger U, Scholz M, Berry W, Mukherjee SD, Winquist E, Haas NB, Foley MA, Dmuchowski C, Perabo F, Hirmand M, Hasabou N, Rathkopf D, for The Enzalutamide Expanded Access Study Investigators (2015) Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America. Prostate 75(8):836–844

    PubMed  PubMed Central  CAS  Google Scholar 

  58. Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, Muraglia A, Porcaro AB, Siracusano S, Brunelli M, Mazzarotto R, Artibani W, Tortora G (2018) The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer 16(3):e645–e653

    PubMed  Google Scholar 

  59. Attard G, Mersebburger AS, Wiebke A et al (2019) Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer: a randomized, open-label phase 2 study. JAMA Oncol 5(8):1159–1167

    PubMed  PubMed Central  Google Scholar 

  60. Tolcher AW, Chi KN, Shore ND, Pili R, Molina A, Acharya M, Kheoh T, Jiao JJ, Gonzalez M, Trinh A, Pankras C, Tran N (2012) Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Cemother Pharmacol 70(2):305–313

    CAS  Google Scholar 

  61. Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido JM, Galli L, Londhe A, de Porre P, Goon B, Lee E, McGowan T, Naini V, Todd MB, Molina A, George DJ, Abiraterone Global EAP Investigators (2014) Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncol 15(11):1263–1268

    PubMed  CAS  Google Scholar 

  62. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PFA, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F (2014) Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 66(5):815–825

    PubMed  PubMed Central  CAS  Google Scholar 

  63. Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF, STOPCaP Abiraterone Collaborators (2017) Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer 84:88–101

    PubMed  PubMed Central  CAS  Google Scholar 

  64. Campora S, Campazzi E, Zanardi S, Puntoni M, Piccininno M, Piccardo A, Shoushtari Zadeh Naseri M, Defferrari C, Provinciali N, Petrera M, Marra D, Biscaldi E, Antonucci GC, Ricci D, Clavarezza M, Gennari A, Gozza A, D'Amico M, Mori M, DeCensi A (2016) Association of biomarkers with serious cardiac adverse events during abiraterone acetate treatment in castration resistant prostate cancer. Transl Oncol 9(6):600–605

    PubMed  PubMed Central  Google Scholar 

  65. Procopio G, Grassi P, Testa I, Verzoni E, Torri V, Salvioni R, Valdagni R, de Braud F (2015) Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors. Am J Clin Oncol 38(5):479–482

    PubMed  CAS  Google Scholar 

  66. Maines F, Caffo O, De Giorgi U et al (2016) Safety and clinical outcomes of abiraterone acetate after docetaxel in octogenarians with metastatic castration-resistant prostate cancer: results of the Italian compassionate use named patient programme. Clin Genitourin Cancer 14(1):48–55

    PubMed  Google Scholar 

  67. Prati V, Ruatta F, Aversa C, Gernone A, Galizia D, Bonzano A, Torino S, Nuzzolese I, Marandino L, Aglietta M, Ortega C (2018) Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation. Future Oncol 14(5):443–448

    PubMed  CAS  Google Scholar 

  68. Merseburger AS, Hammerer P, Rozet F (2015) el al. Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World J Urol 33(8):179–185

    Google Scholar 

  69. Morgia G, Russo GI, Tubaro A et al (2016) Prevalence of cardiovascular disease and osteoporosis during androgen deprivation therapy prescription discordant to EAU guidelines: results from a multicenter, cross-sectional analysis from the CHOsIng Treatment for Prostate canCEr (CHOICE) Study. Urology 96:165–170

    PubMed  Google Scholar 

  70. Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, Steineck G, Wiklund NP (2017) Effect of comorbidity on prostate cancer-specific mortality: a prospective observational study. J Clin Oncol 35(31):3566–3574

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Oncology Unit, Istituto Neurotraumatologico Italiano (I.N.I.) Grottaferrata, via di S.Anna snc, Grottaferrata, 00046, Rome, Italy

    Vittore Cereda, Pina T. Falbo, Gaia Manna, Alessandro Iannace, Antonello Menghi, Michela Corona, Diana Semenova & Gaetano Lanzetta

  2. Division of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169, Rome, Italy

    Leonardo Calò

  3. Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, 04100, Latina, Italy

    Roberto Carnevale & Giacomo Frati

Authors
  1. Vittore Cereda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pina T. Falbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gaia Manna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandro Iannace
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Antonello Menghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michela Corona
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Diana Semenova
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Leonardo Calò
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Roberto Carnevale
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Giacomo Frati
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Gaetano Lanzetta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vittore Cereda.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cereda, V., Falbo, P.T., Manna, G. et al. Hormonal prostate cancer therapies and cardiovascular disease: a systematic review. Heart Fail Rev 27, 119–134 (2022). https://doi.org/10.1007/s10741-020-09984-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-020-09984-2

Keywords

Search

Navigation